



ENTERGY

Entergy Operations, Inc.

1448 S.R. 333

Russellville, AR 72801

Tel 501 858-6000

April 26, 1995

0CAN049510

U. S. Nuclear Regulatory Commission
Document Control Desk
Mail Station P1-137
Washington, DC 20555

Subject: Arkansas Nuclear One - Units 1 and 2
Docket Nos. 50-313 and 50-368
License Nos. DPR-51 and NPF-6
Drug Testing Laboratory Performance Report

Gentlemen:

As part of the routine blind performance drug testing program, a spiked sample certified to be "positive" for amphetamine was screened "positive" for the presence of amphetamine by Arkansas Nuclear One (ANO) Fitness For Duty personnel and submitted to the SmithKline Beecham Clinical Laboratories on December 30, 1994. The result of this test was released to ANO on January 2, 1995, as "negative." Upon receipt of this test report, ANO sent a second aliquot of the same sample to SmithKline Beecham on January 4, 1995. On January 11, 1995, the laboratory reported that the second aliquot had been screened "positive" and confirmed "positive" for amphetamine. Due to the discrepancy between test results from the same sample, an investigation was requested of SmithKline Beecham on January 27, 1995. ANO sent letters to SmithKline Beecham on February 14, 1995, and March 23, 1995, requesting the investigation results. ANO received the report of the investigation dated March 28, 1995, on March 31, 1995. This report states that the original aliquot was screened "positive" for amphetamine; however, due to an error by a technician, it was not submitted for gas chromatography/mass spectrometry (GC/MS) and was erroneously reported as "negative."


In accordance with paragraph 2.8(e)(4) of Appendix "A" to 10CFR26, enclosed is the investigation report provided to ANO by SmithKline Beecham concerning the unsatisfactory performance test result.

9505030163 950426
PDR ADOCK 05000313
P PDR

A022
11

The enclosure to the SmithKline Beecham letter is not being transmitted because it contains confidential information regarding other positive samples that does not assist in understanding the condition. A copy of the enclosure is available for review at ANO.

Very truly yours,


Dwight C. Mims
Director, Licensing

DCM/tfs

Enclosure

cc: Mr. Leonard J. Callan
Regional Administrator
U. S. Nuclear Regulatory Commission
Region IV
611 Ryan Plaza Drive, Suite 400
Arlington, TX 76011-8064

NRC Senior Resident Inspector
Arkansas Nuclear One
1448 S. R. 333
Russellville, AR 72801

Mr. George Kalman
NRR Project Manager Region IV/ANO-1 & 2
U. S. Nuclear Regulatory Commission
NRR Mail Stop 13-H-3
One White Flint North
11555 Rockville Pike
Rockville, MD 20852

Dr. Michael Schaffer
Director of Toxicology
SmithKline Beecham Clinical Laboratories
801 E. Dixie Ave.
Leesburg, FL 34748

SB
SmithKline Beecham
Clinical Laboratories

Michael I. Schaffer, Ph.D.

March 28, 1995

Jerry F. Hodges, M.D., MRO
Arkansas Nuclear One
Entergy Operations, Inc.
1448 SR 333
Russellville, AR 72801

RE: LB2147
273815F

Dear Dr. Hodges:


The above mentioned specimen was submitted for testing on 30 December 1994. It was received into the laboratory on 31 December 1994. The sample was aliquotted for testing on the Abbott TDX analyzer. It appears on the TDX printout as specimen number 9, with the result HI \geq T. The result for that test was a positive result. The technician errored and entered the result as a negative instead of the positive. The result was released as a negative on 2 January 1995.

Receipt of your letter and the submission of this sample for GC/MS confirmation revealed a positive amphetamine and methamphetamine. This specimen result was released under the accession number 277149F. The concentrations of amphetamine and methamphetamine determined were 1169 and 1196 ng/ml respectively. Copies of the first TDX printout, and a copy of the MFR are enclosed.

The individuals involved have been counseled in this matter. We sincerely regret this occurrence, and have informed all staff involved in the Abbott TDX methodology to pay closer attention to detail in this area, as this process is a manual one.

We respectively regret the negative entry on the first result. I hope that this information resolves this to your satisfaction.

Respectively submitted,



Michael I. Schaffer, Ph.D., D.A.B.F.T.
Director Of Toxicology

CX: R. T. Chamberlain, J.D., Ph.D.
Kathe Russell, B.S.

Enclosure

